Rosa/KressWorks Foundation completes first milestone in development of Ewing's sarcoma PhysioPD Platform

Mar 29 2014

Rosa & Co. LLC and the KressWorks Foundation are pleased to announce the completion of the Ewing's sarcoma PhysioMap®. Completion of the PhysioMap is the first milestone in the development of the Ewing's sarcoma PhysioPD Platform. The Ewing's sarcoma PhysioMap was created to provide a formalized, graphical representation of key biological systems and processes underlying Ewing's sarcoma disease progression and associated therapeutic interventions. The PhysioMap contains the Hallmarks of Cancer, cancer-promoting processes, such as sustained proliferative signaling and resistance to cell death which integrate signals from biological pathways, controlling the growth, proliferation, and metastatic potential of the cancer cells.

When the Ewing's sarcoma PhysioMap is converted into a PhysioPD Platform, it will be used to understand the signaling pathways contributing to disease progression and investigate the mechanisms underlying the response to standard-of-care chemotherapeutic regimens.  The KressWorks Foundation plans to incorporate the PhysioPD Platform into a Systematic Treatment Methodology that will combine computational models with clinical measurements to provide optimized treatment regimens for individual cancer patients.

Source: Rosa & Co.